Bio-Techne Corporation
TECH
Classement en actions
#1869
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures,... Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Prix de l'action
$72.55
Dernière synchronisation: 2026-10-16
Capitalisation boursière
$11.38B
Changement (1 jour)
0.03%
Changement (1 an)
17.27%
Pays
US
Échange Bio-Techne Corporation (TECH)
Catégorie
Healthcare
Bénéfices pour Bio-Techne Corporation (TECH)
Bénéfices en Jun 2026 TTM : $240.68M
Selon les derniers rapports financiers de Bio-Techne Corporation, les bénéfices actuels de l'entreprise sont de $240.68M. En 2024, l'entreprise a réalisé un bénéfice de $185.69M, une diminution par rapport à celui de 2023 qui était de $338.66M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Bio-Techne Corporation de 2000 à 2026
Bénéfices à la fin de chaque année
| Année | Bénéfices | Changez |
|---|---|---|
| 2026 (TTM) | $240.68M | 144.44% |
| 2025 | $98.46M | -46.97% |
| 2024 | $185.69M | -45.17% |
| 2023 | $338.66M | 12.37% |
| 2022 | $301.39M | 103.40% |
| 2021 | $148.18M | -46.41% |
| 2020 | $276.48M | 146.82% |
| 2019 | $112.02M | -11.07% |
| 2018 | $125.95M | 11.30% |
| 2017 | $113.16M | -23.27% |
| 2016 | $147.48M | -4.33% |
| 2015 | $154.16M | -4.48% |
| 2014 | $161.39M | 0.45% |
| 2013 | $160.66M | -0.95% |
| 2012 | $162.20M | -1.69% |
| 2011 | $164.98M | 5.46% |
| 2010 | $156.45M | 0.70% |
| 2009 | $155.36M | 1.00% |
| 2008 | $153.83M | 19.31% |
| 2007 | $128.93M | 15.98% |
| 2006 | $111.16M | 11.29% |
| 2005 | $99.89M | 21.02% |
| 2004 | $82.54M | 18.67% |
| 2003 | $69.56M | 84.32% |
| 2002 | $37.74M | -21.07% |
| 2001 | $47.81M | 21.30% |
| 2000 | $39.41M | 0.00% |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise | Bénéfices | Différence de bénéfices | Pays |
|---|---|---|---|
| $5.27B | 2,091.67% |
US
|
|
| $-3.09B | -1,382.62% |
US
|
|
| $-4.02B | -1,768.69% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 710.47% |
NL
|
